Subacute CNS demyelination after treatment with nivolumab for melanoma

Cancer Immunology Research

Volumn 3, Issue 12, 2015, Pages 1299-1302

  Maurice, Catherine ^a   Schneider, Raphael ^b   Kiehl, Tim Rasmus ^c,d   Bavi, Prashant ^c   Roehrl, Michael H A ^c,d   Mason, Warren P ^a   Hogg, David ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEMYELINATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMAGE ANALYSIS; LUMBAR PUNCTURE; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING; WHITE MATTER LESION; CHEMICALLY INDUCED; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; DEMYELINATING DISEASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84962439197     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0141     Document Type: Article

References (19)

1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
2. Conry RM, Sullivan JC, Nabors LB3rd: Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 2015;3: 598-601.
3. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013;1291:1-13.
4. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
7. Iwai Y, IshidaM, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99: 12293-7.
8. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192-8.
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
10. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci 2012;15:1096-101.
11. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F , et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:71-8.
12. Yogev N, Frommer F, Lukas D, Kautz-Neu K, Karram K, Ielo D, et al. Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. Immunity 2012;37: 264-75.
13. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009;183:4984-93.
14. Pittet CL, Newcombe J, Prat A. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011;8:15518.
15. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 2012;120:4772-82.
16. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
17. Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013;48:440-4.
18. Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, RichardMA, Grob JJ. A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: A differential diagnosis for ipilimumab-induced colitis. J Immunother 2013;36:77-8.
19. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589-93.